380844-22-4

Basic information

• Product Name: Benzoic acid, 3-(3-chloropropoxy)-4-methoxy-, methyl ester
• CAS NO: 380844-22-4
• Molecular Formula: C12H15ClO4
• Molecular Weight: 258.702
• Mol File: 380844-22-4.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-(3-chloropropoxy)-4-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-(3-chloropropoxy)-4-methoxy-, methyl ester(380844-22-4)
• EPA Substance Registry System: Benzoic acid, 3-(3-chloropropoxy)-4-methoxy-, methyl ester(380844-22-4)

Safety Data

• Hazardous Substances Data: 380844-22-4(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 929683-54-5 3-(3-chloropropoxy)-4-methoxybenzaldehyde 
• 621-59-0 isovanillin 
• 645-08-9 Isovanillic acid 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 109-70-6 1.3-chlorobromopropane 
• 632-02-0 3-chloropropyl p-toluenesulfonate 

Downstream Products

• 1259017-55-4 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-(bis(4-fluorophenyl)methyl)piperazine-1-carbodithioate 
• 1259017-73-6 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(3-chloropropoxy)-7-methoxyquina-zolin-4-amine 
• 1259017-72-5 N-(3-bromophenyl)-6-(3-chloropropoxy)-7-methoxyquinazolin-4-amine 
• 1259017-50-9 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-methylpiperazine-1-carbodithioate 
• 1259017-48-5 3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-methylpiperazine-1-carbodithioate 
• 1259017-46-3 3-(4-(3-bromophenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-methylpiperazine-1-carbodithioate 
• 1259017-51-0 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl piperazine-1-carbodithioate 
• 1259017-53-2 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl morpholine-4-carbodithioate 
• 1259017-54-3 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl thiomorpholine-4-carbodithioate 
• 214472-17-0 4-methoxy-5-[3-(4-morpholinyl)propoxy]benzoic acid methyl ester 
• 1456070-15-7 C₂₃H₂₄ClFN₄O₂S 
• 1456070-14-6 C₂₃H₂₄ClFN₄O₃ 
• 1445860-67-2 4-(3'-chloro-4'-fluorophenylamino)-6-[3-(2-oxa-6-azaspiro[3.3]heptane-6-yl)propoxy]-7-methoxyquinazoline 
• 1445860-68-3 4-(3'-chloro-4'-fluorophenylamino)-6-[3-(2-oxa-6-azaspiro[3.4]octane-6-yl)propoxy]-7-methoxyquinazoline 

Relevant articles and documents

Novel anti-tumor compounds

The present invention provides a novel anti-tumor compound. The compound is a compound shown in formula (I) or pharmaceutically accepted salt or a solvate of the salt. Further provided is a pharmaceutical composition. The pharmaceutical composition compri

Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines

On the basis of combination strategy, a novel series of EGFR inhibitors were designed and synthesized by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. The effect of the synthesized compounds on cell proliferation was evaluated by MTT assay in three human cancer cell lines: MDA-MB-468, SK-BR-3 and HCT-116. Two compounds (11d and 11f) were found more potent against all three cell lines and five compounds (11a, 11d-11g) were found more potent against both MDA-MB-468 and SK-BR-3 than Lapatinib. SAR studies revealed that the substituents on C6 and C7 positions of quinazoline, the amine component of dithiocarbamate moiety and the linker greatly affected the activity. This work provides a promising new strategy for the preparation of potent tyrosine kinase inhibitors.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors

Aryl phenyl ureas with a 4-quinazolinoxy substituent at the meta-position of the phenyl ring are potent inhibitors of mutant and wild type BRAF kinase. Compound 7 (1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy) phenyl)urea hydrochloride) exhibits good pharmacokinetic properties in rat and mouse and is efficacious in a mouse tumor xenograft model following oral dosing.